Bedrijfsoverzicht
Solid Biosciences Inc. is a biotechnology enterprise dedicated to developing advanced therapeutic solutions for neuromuscular and cardiac diseases within the United States market. The company's primary focus centers on its lead product candidate, SGT-003, which is currently advancing through phase 1/2 clinical trials for the treatment of Duchenne muscular dystrophy, alongside the development of SGT-212 for Friedreich's ataxia. Operating within the broader Healthcare sector and specifically the Biotechnology industry, the firm leverages specialized research and development capabilities to address unmet medical needs in rare disease populations. The company's scale is defined by a market capitalization of $789.10M and a workforce comprising 121 employees, indicating a mid-stage biopharmaceutical entity with a significant valuation relative to its headcount. While the company reports no revenue figures in the provided data, the market capitalization of $789.10M suggests a substantial market confidence in the potential value of its pipeline assets despite the pre-revenue status typical of companies in phase 1/2 clinical development.
Financiële gezondheid
Solid Biosciences Inc. reports a net income of $-174,324,992 and an EBITDA of $-177,570,000, while revenue and price-to-sales metrics are not available for the trailing twelve months. The substantial gap between revenue and net income, combined with the absence of reported revenue, indicates that the company is in an intensive investment phase where operating expenses and clinical trial costs are being capitalized against minimal or unreported sales, resulting in significant net losses. The company's free cash flow stands at $-99,700,752, which reflects a heavy consumption of cash resources to fund ongoing research, development, and clinical trial activities rather than generating cash from operations. Three margin metrics—gross margin, operating margin, and profit margin—are all recorded at 0.0%, a figure consistent with early-stage biotechnology firms that have not yet achieved commercial product sales to generate positive gross or operating profits. On the balance sheet, the company holds $187.85M in cash against $21.16M in debt, resulting in a debt-to-equity ratio of 11.76, which characterizes a leveraged balance sheet relative to equity but highlights a strong liquidity position due to the high cash reserve. The current ratio is 6.14, indicating a robust ability to meet short-term obligations with its liquid assets, providing financial flexibility to sustain operations during the lengthy clinical development cycles. Furthermore, the return on equity is -109.9% and the return on assets is -53.2%, metrics that reveal the company is currently diluting shareholder value and utilizing assets to generate negative returns as it burns cash to advance its therapeutic candidates.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is not available due to the lack of net income, while the forward P/E is listed at -4.76, a negative figure that implies the market is pricing in a trajectory where earnings are expected to remain negative or are insufficient to justify a traditional earnings-based multiple. The price-to-book ratio is 3.52, indicating that the market values the company at a significant premium over its tangible book value, which is typical for biotechnology firms where intellectual property and pipeline potential outweigh current asset bases. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA are also recorded as N/A or -3.50 respectively, suggesting that traditional valuation multiples are not applicable given the pre-commercial nature of the business and negative earnings. The stock has traded within a 52-week range with a high of $8.72 and a low of $2.41, providing a context for price volatility and historical trading bounds relative to the current valuation. The beta of 2.58 indicates that the stock exhibits high price volatility, moving with approximately 2.58 times the magnitude of the broader market, which reflects the high risk profile associated with investing in clinical-stage biotechnology companies.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, meaning that traditional growth rate comparisons cannot be calculated without historical comparative data, yet the negative earnings growth relative to zero revenue underscores the company's current focus on expenditure rather than profit generation. As a non-dividend payer, the company does not distribute a dividend yield or a payout ratio, as evidenced by the 0.0% payout ratio and N/A dividend yield figures. Consequently, the company reinvests all available capital and operational cash flow back into the development of its neuromuscular and cardiac disease therapies rather than returning cash to shareholders. This growth and income profile is characteristic of a capital-intensive biotechnology firm that prioritizes clinical trial progression and asset expansion over immediate income distribution or profitability.